Fredun Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Fredun Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 9 Products, $6.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fredun Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 9 Products, $6.7M Trade | TransData Nexus

Fredun Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $6.7M Total Trade · DGFT Verified

Fredun Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $6.7M across 9 products in 6 therapeutic categories. Based on 137 verified export shipments from Indian Customs (DGFT) records, Fredun Pharmaceuticals Limited is the #1 Indian exporter in 1 product including Iodex. Top exports include Sitagliptin ($2.8M), Simvastatin ($950.0K), Iodex ($660.2K).

Fredun Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Fredun Pharmaceuticals Limited pharmaceutical export portfolio — 9 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Fredun Pharmaceuticals Limited? — Company Overview & Market Position

Fredun Pharmaceuticals Limited, established in 1987, is a Mumbai-based pharmaceutical company specializing in the manufacturing and export of finished pharmaceutical formulations, dietary and herbal supplements, nutraceuticals, and other healthcare products. The company operates under the Corporate Identification Number (CIN) L24239MH1987PLC043662 and is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 539730. As of March 11, 2026, Fredun Pharmaceuticals reported a market capitalization of approximately INR 7.93 billion, reflecting significant growth over the past year. The company employs around 261 individuals, with a revenue per employee ratio of INR 22.64 million, indicating efficient operations. Fredun Pharmaceuticals exports its products to various regions, including Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries, and Latin America.

What Does Fredun Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Sitagliptin$2.8M 2Simvastatin

Product Portfolio — Top 9 by Export Value

Fredun Pharmaceuticals Limited exports 9 pharmaceutical products across 6 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Sitagliptin	Diabetes & Endocrine	$2.8M	56	3.7%	5
2	Simvastatin	Cardiovascular	$950.0K	19	0.8%	8
3	Iodex	Brand Names & OTC Products	$660.2K	16	9.1%	1
4	Bisoprolol	Cardiovascular	$550.0K	11	0.7%	2
5	Spironolactone	Diuretics	$500.0K	10	0.3%	9
6	Tramadol	Analgesics & Antipyretics	$450.0K	9	0.1%	13
7	Clopidogrel	Cardiovascular	$400.0K	8	0.2%	6
8	Dexamethasone	Corticosteroids	$200.0K	4	0.1%	5
9	Glimepiride	Diabetes & Endocrine	$200.0K	4	0.3%	7

Fredun Pharmaceuticals Limited exports 9 pharmaceutical products across 6 therapeutic categories with a total export value of $6.7M. The company is the #1 Indian exporter in 1 product: Iodex. The top category is Diabetes & Endocrine (44.7% of portfolio), followed by Cardiovascular (28.3%), indicating a concentrated portfolio with the top 5 products accounting for 81.4% of total export value.

Fredun Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Fredun Pharmaceuticals operates manufacturing facilities in Mumbai, India, where it produces a diverse range of pharmaceutical formulations, dietary supplements, and healthcare products. The company specializes in allopathic formulations, including analgesics, antacids, anti-diabetics, anti-inflammatories, and anti-malarials, among others. Additionally, Fredun Pharmaceuticals offers surgical products such as IV fluids, disposable syringes, infusion sets, surgical gloves, and personal healthcare items. The manufacturing facilities are equipped to meet both domestic and international standards, ensuring the production of high-quality pharmaceutical products.

3Key Leadership

Fredun Pharmaceuticals is led by a team of experienced executives. Mr. Fredun Nariman Medhora serves as the Managing Director and Chief Financial Officer, overseeing the company's strategic direction and financial operations. Mr. Daulat N. Medhora holds the position of Executive Chairman and Joint Managing Director, contributing to the company's leadership and decision-making processes. Other key executives include Ms. Daisy Cyril D’souza, appointed as a Non-Executive Independent Director in January 2024, and Ms. Sonal Dharmin Desai, who joined as a Non-Executive Independent Director in January 2025. The leadership team is committed to driving the company's growth and maintaining its reputation in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Fredun Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Fredun Pharmaceuticals has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports a range of pharmaceutical formulations to these regions, adhering to the regulatory requirements set by authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and Therapeutic Goods Administration (TGA). While specific details regarding regulatory filings and approvals are not publicly disclosed, Fredun Pharmaceuticals' export activities suggest compliance with the stringent standards of these markets. The company's commitment to quality and regulatory adherence is evident in its diverse product portfolio and international reach.

2Emerging Markets

Fredun Pharmaceuticals has expanded its footprint into emerging markets, including Africa, Latin America, and Southeast Asia. The company's export activities in these regions are facilitated by its adherence to international quality standards, enabling access to markets with growing pharmaceutical demands. While specific details regarding WHO prequalification are not publicly available, Fredun Pharmaceuticals' export activities suggest a focus on meeting international quality standards to enhance market access. The company's strategic expansion into these regions reflects its commitment to addressing the healthcare needs of diverse populations.

Fredun Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Fredun Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the company's export activities to the United States suggest compliance with FDA regulations. Fredun Pharmaceuticals' commitment to quality and regulatory adherence is evident in its diverse product portfolio and international reach. The company's strategic focus on regulated markets indicates a proactive approach to meeting the standards set by authorities such as the FDA.

2WHO & EU GMP

While specific details regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certifications are not publicly available, Fredun Pharmaceuticals' export activities to regions requiring such certifications suggest adherence to international quality standards. The company's commitment to quality is further demonstrated by its diverse product portfolio and international reach. Fredun Pharmaceuticals' strategic focus on regulated markets indicates a proactive approach to meeting the standards set by authorities such as the World Health Organization (WHO) and the European Medicines Agency (EMA).

CDSCO & Indian Regulatory

Fredun Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Fredun Pharmaceuticals operates in a competitive landscape, with several companies offering similar pharmaceutical formulations and healthcare products. While specific market share comparisons are not publicly available, Fredun Pharmaceuticals' diverse product portfolio and export activities indicate a significant presence in its target markets. The company's focus on quality and regulatory compliance positions it favorably against competitors in overlapping categories. Fredun Pharmaceuticals' strategic expansion into emerging markets further enhances its competitive standing.

2Key Differentiators

Fredun Pharmaceuticals' key differentiators include its diverse product portfolio, encompassing a wide range of pharmaceutical formulations, dietary supplements, and healthcare products. The company's commitment to quality and regulatory compliance ensures that its products meet international standards, facilitating access to various global markets. Fredun Pharmaceuticals' strategic focus on emerging markets demonstrates its proactive approach to addressing the healthcare needs of diverse populations.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Fredun Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Fredun Pharmaceuticals has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products, with a total export value of $6.7 million USD across 137 shipments from 2022 to 2026. The company's portfolio includes nine products across six therapeutic categories, with the top five products accounting for 81.4% of the total export value. This indicates a focused and reliable supply chain capable of meeting international demand. Fredun Pharmaceuticals' adherence to regulatory standards and commitment to quality further enhance its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Fredun Pharmaceuticals as a supplier:

FDA Registration: Confirm that the manufacturing facilities are registered with the U.S. Food and Drug Administration. Verification can be done through the FDA's Establishment Registration & Device Listing database.

WHO-GMP Certification: Ensure that the company holds Good Manufacturing Practice certification from the World Health Organization. This can be verified through the WHO's official website or by contacting the company directly.

Frequently Asked Questions — Fredun Pharmaceuticals Limited

How many pharmaceutical products does Fredun Pharmaceuticals Limited export from India?

Fredun Pharmaceuticals Limited exports 9 pharmaceutical products across 6 therapeutic categories. The top exports are Sitagliptin ($2.8M), Simvastatin ($950.0K), Iodex ($660.2K), Bisoprolol ($550.0K), Spironolactone ($500.0K). Total export value is $6.7M.

What is Fredun Pharmaceuticals Limited's total pharmaceutical export value?

Fredun Pharmaceuticals Limited's total pharmaceutical export value is $6.7M, based on 137 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Fredun Pharmaceuticals Limited the #1 Indian exporter?

Fredun Pharmaceuticals Limited is the #1 Indian exporter in 1 products: Iodex (9.1% market share).

What therapeutic categories does Fredun Pharmaceuticals Limited cover?

Fredun Pharmaceuticals Limited exports across 6 therapeutic categories. The largest are Diabetes & Endocrine (44.7%, 2 products), Cardiovascular (28.3%, 3 products), Brand Names & OTC Products (9.8%, 1 products).

Get Full Fredun Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.